共 191 条
[1]
Andre T(2009)Improved overall survival with Oxaliplatin, fluorouracil, and Leucovorin as adjuvant treatment in stage II or III Colon Cancer in the MOSAIC trial J Clin Oncol 27 3109-3116
[2]
Boni C(2014)Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials Lancet Oncol. 15 1481-1492
[3]
Navarro M(2013)Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 24 vi64-vi72
[4]
Tabernero J(2014)Colon cancer, version 3.2014 J Natl Compr Cancer Netw 12 1028-1059
[5]
Hickish T(2022)A national evaluation of the predictors of compliance and survival from adjuvant chemotherapy in high-risk stage II colon cancer: a National Cancer Database (NCDB) analysis Surgery. 172 859-868
[6]
Topham C(2021)Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial Ann Oncol 32 77-84
[7]
Schmoll HJ(2007)Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803 J Clin Oncol 25 3456-3461
[8]
Twelves C(2014)Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial Lancet Oncol 15 862-873
[9]
Sun W(2017)Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial Ann Oncol 28 3110-1188
[10]
O’Connell MJ(2018)Duration of adjuvant chemotherapy for stage III Colon Cancer N Engl J Med 378 1177-161